Core Viewpoint - Eos Energy Enterprises, Inc. is facing a class action lawsuit for alleged violations of the Securities Exchange Act of 1934, with significant financial losses reported during the class period from November 5, 2025, to February 26, 2026 [1][3]. Company Overview - Eos Energy designs, manufactures, and markets zinc-based battery energy storage systems aimed at utility-scale commercial and industrial applications [2]. Allegations of the Lawsuit - The lawsuit claims that Eos Energy made false or misleading statements and failed to disclose critical operational issues, including: - Inability to achieve production ramp-up and capacity utilization as per guidance [3]. - Battery line downtime exceeding industry norms and internal forecasts [3]. - Delays in automated bipolar production quality targets [3]. - Inadequate systems preventing accurate guidance and timely disclosures [3]. Financial Performance - On February 26, 2026, Eos Energy reported its fourth quarter and full year 2025 results, revealing: - Full year 2025 revenue of $114.2 million, significantly below the guidance of $150 million to $160 million [4]. - A gross loss of $143.8 million and a net loss attributable to shareholders of $969.6 million [4]. - An adjusted EBITDA loss of $219.1 million and a capacity milestone reached five weeks later than planned [4]. - Following this announcement, Eos Energy's stock price fell by more than 39% [4]. Legal Process - Investors who purchased Eos Energy securities during the class period can seek appointment as lead plaintiff in the class action lawsuit, representing the interests of all class members [5].

Core Viewpoint - The Boston Scientific Corporation is facing a class action lawsuit for alleged violations of the Securities Exchange Act of 1934, with claims that the company misled investors regarding its financial outlook and market position [1][4]. Company Overview - Boston Scientific develops, manufactures, and markets medical devices for various interventional medical specialties globally [3]. Allegations of the Lawsuit - The lawsuit alleges that Boston Scientific and its executives made false or misleading statements about the company's revenue outlook and growth potential, downplaying risks from seasonality and macroeconomic factors [4]. - It is claimed that Boston Scientific's goal to grow its share in the electrophysiology market at "2x the market" was unrealistic due to new competition affecting its market share [4]. Financial Performance - On February 4, 2026, Boston Scientific reported its fourth quarter and full year 2025 financial results, revealing: - Fourth quarter GAAP net income of $672 million ($0.45 per share), up from $566 million ($0.38 per share) a year prior, with adjusted EPS of $0.80 compared to $0.70 a year ago [5]. - Full year GAAP net income of $2.898 billion ($1.94 per share), compared to $1.853 billion ($1.25 per share) the previous year, with full year adjusted EPS of $3.06 versus $2.51 a year ago [5]. - The reported GAAP net income per share of $0.45 fell short of the company's guidance range of $0.48 to $0.52, leading to a stock price drop of over 17% [5]. Lead Plaintiff Process - The Private Securities Litigation Reform Act of 1995 allows any investor who purchased Boston Scientific common stock during the class period to seek appointment as lead plaintiff in the lawsuit [6]. - The lead plaintiff represents the interests of all class members and can select a law firm for litigation [6]. Law Firm Background - Robbins Geller Rudman & Dowd LLP is a leading law firm specializing in securities fraud and shareholder rights litigation, having recovered over $916 million for investors in 2025 alone [7]. - The firm has a strong track record, recovering $8.4 billion for investors over the past five years, including the largest securities class action recovery in history [7].

Core Viewpoint - Enphase Energy, Inc. is facing a class action lawsuit due to allegations of misleading statements regarding its financial and operational prospects, particularly related to inventory management and the impact of the expiration of the Residential Clean Energy Credit [1] Group 1: Class Action Lawsuit Details - The class action lawsuit, titled Tripathi v. Enphase Energy, Inc., is filed against Enphase Energy and its executives for violations of the Securities Exchange Act of 1934 [1] - Investors who purchased Enphase Energy securities between April 22, 2025, and October 28, 2025, can seek to be appointed as lead plaintiff by April 20, 2026 [1] - The lawsuit alleges that Enphase Energy overstated its ability to manage channel inventory and mitigate the effects of the termination of the 25D Credit, leading to inflated financial expectations [1] Group 2: Financial Impact and Stock Performance - On October 28, 2025, Enphase Energy reported third-quarter financial results, indicating that elevated channel inventory would lead to lower battery storage shipments in Q4 2025 and that the expiration of the 25D Credit would negatively impact Q1 2026 revenues [1] - Following this announcement, Enphase Energy's stock price fell by more than 15% [1] Group 3: Law Firm Background - Robbins Geller Rudman & Dowd LLP is a leading law firm specializing in securities fraud and shareholder rights litigation, having recovered over $916 million for investors in 2025 alone [1] - The firm has a strong track record, recovering $8.4 billion for investors over the past five years, making it one of the largest plaintiffs' firms globally [1]

Core Viewpoint - The PayPal class action lawsuit alleges that the company and certain executives misled investors regarding the company's revenue outlook and growth potential during the Class Period, leading to significant financial losses for shareholders [3][4]. Group 1: Lawsuit Details - The class action lawsuit, titled Darcy v. PayPal Holdings, Inc., allows investors who purchased PayPal common stock between February 25, 2025, and February 2, 2026, to seek appointment as lead plaintiff by April 20, 2026 [1]. - The lawsuit claims that PayPal's management created a false impression of reliable revenue projections while downplaying risks associated with seasonality and macroeconomic factors [3]. - On February 3, 2026, PayPal reported disappointing earnings for Q4 and the full fiscal year 2025, which included a decline in Branded Checkout performance and the withdrawal of previously set 2027 financial targets [4]. Group 2: Financial Impact - Following the announcement of poor financial results and the transition of CEO James Alexander Chriss, PayPal's stock price dropped by more than 20% [4]. - The lawsuit cites that the optimistic growth plans were unrealistic and required stable consumer conditions and effective management execution, which were not met [3]. Group 3: Legal Process - The Private Securities Litigation Reform Act of 1995 allows any investor who acquired PayPal stock during the Class Period to apply as lead plaintiff, representing the interests of the class [5]. - The lead plaintiff has the authority to select a law firm for the lawsuit and does not need to be the lead plaintiff to benefit from any potential recovery [5]. Group 4: Law Firm Background - Robbins Geller Rudman & Dowd LLP is a leading law firm in securities fraud and shareholder rights litigation, having recovered over $916 million for investors in 2025 alone [6]. - The firm has achieved significant recoveries in securities class action cases, totaling $8.4 billion over the past five years, with a notable recovery of $7.2 billion in the Enron case [6].

Core Viewpoint - The Navan class action lawsuit alleges that Navan, Inc. and its executives misled investors regarding the company's financial health during its IPO, leading to significant stock price declines after the announcement of increased expenses [3][4][5]. Group 1: Class Action Lawsuit Details - The lawsuit, titled McCown v. Navan, Inc., allows purchasers of Navan's common stock from its October 31, 2025 IPO to seek lead plaintiff status by April 24, 2026 [1]. - Navan's IPO involved the issuance of nearly 37 million shares at an offering price of $25.00 per share [2]. - The lawsuit claims that the IPO documents were materially misleading, particularly regarding a 39% increase in sales and marketing expenses shortly after the IPO [3]. Group 2: Financial Impact and Stock Performance - On December 15, 2025, Navan reported a 39% increase in sales and marketing expenses, rising to nearly $95 million from $68.5 million in the previous quarter [4]. - Following this announcement, Navan's stock price fell nearly 12% [4]. - By the time the lawsuit commenced, Navan's stock had dropped to as low as $9.20 per share, representing a decline of nearly 63% from the IPO price [5]. Group 3: Legal Process and Firm Background - The Private Securities Litigation Reform Act of 1995 allows investors who purchased Navan stock during the IPO to seek lead plaintiff status, representing the interests of the class [6]. - Robbins Geller Rudman & Dowd LLP, the law firm handling the case, is recognized as a leading firm in securities fraud litigation, having recovered over $916 million for investors in 2025 alone [7].

Core Viewpoint - Driven Brands Holdings Inc. is facing a class action lawsuit due to alleged violations of the Securities Exchange Act of 1934, with significant financial misstatements impacting its stock value [1][3][4]. Summary by Sections Class Action Lawsuit Details - The class action lawsuit is titled Clark v. Driven Brands Holdings Inc., and it involves purchasers of Driven Brands common stock from May 9, 2023, to February 24, 2026 [1]. - Investors have until May 8, 2026, to seek appointment as lead plaintiff in the lawsuit [1]. Allegations Against Driven Brands - The lawsuit alleges that Driven Brands made false or misleading statements and failed to disclose critical errors in financial reporting, including: - Errors in lease recording affecting right of use assets and liabilities as of December 28, 2024, and September 27, 2025 [3]. - Misreporting of cash balances and operating cash flows, leading to overstatements of cash and revenue for fiscal years 2023 and 2024 [3]. - Improper presentation of supply and other expenses as company-operated store expenses for fiscal years 2023 and 2024 [3]. - Additional errors related to income tax provision, revenue recognition, and misclassifications in financial statements for fiscal year 2025 [3]. Impact of Financial Misstatements - On February 25, 2026, Driven Brands disclosed material errors in its previously issued financial statements for fiscal years 2023 and 2024, leading to a nearly 40% drop in its stock price [4]. Lead Plaintiff Process - The Private Securities Litigation Reform Act of 1995 allows any investor who purchased Driven Brands common stock during the class period to seek lead plaintiff status, which involves directing the lawsuit on behalf of all class members [5]. About Robbins Geller - Robbins Geller Rudman & Dowd LLP is a leading law firm specializing in securities fraud and shareholder rights litigation, having recovered over $916 million for investors in 2025 alone [6].

Core Viewpoint - Grabar Law Office is investigating claims on behalf of shareholders of Soleno Therapeutics regarding potential violations of federal securities laws related to misleading statements about the safety and commercial prospects of its drug candidate DCCR (VYKAT XR) [1][3]. Group 1: Investigation Details - The investigation focuses on whether Soleno and its executives made materially false and misleading statements about DCCR, particularly regarding its safety profile and clinical results [1][3]. - A federal securities fraud class action complaint has been filed, alleging that Soleno misrepresented DCCR's safety and efficacy, leading to significant stock price declines [3][7]. Group 2: Stock Performance and Impact - Following disclosures about the risks associated with DCCR, Soleno's stock price fell from a high of over $90 per share to below $45 per share, resulting in substantial losses for investors [3][7]. - The controversy surrounding DCCR has disrupted its commercial launch and negatively impacted physician adoption [7]. Group 3: Safety Concerns - Significant safety concerns regarding DCCR were allegedly downplayed or concealed, including evidence of excess fluid retention in clinical trial participants [7]. - Reports indicated that the integrity of Soleno's clinical trial data was questioned, and there were serious adverse safety events associated with the drug [7].

LOS ANGELES--(BUSINESS WIRE)--The Law Offices of Frank R. Cruz announces an investigation of ChowChow Cloud International Holdings Limited ("CHOW†or the "Company†) (NYSE: CHOW) on behalf of investors concerning the Company's possible violations of federal securities laws. IF YOU ARE AN INVESTOR WHO LOST MONEY ON CHOWCHOW CLOUD INTERNATIONAL HOLDINGS LIMITED (CHOW), CLICK HERE TO INQUIRE ABOUT POTENTIALLY PURSUING A CLAIM TO RECOVER YOUR LOSS. What Is The Investigation About? On or around Septe. ...

Core Viewpoint - Rosen Law Firm has announced a class action lawsuit on behalf of investors who purchased securities of ODDITY Tech Ltd. during the specified Class Period, highlighting potential securities fraud due to misleading statements made by the company [1] Company Details - ODDITY Tech Ltd. is facing allegations that it made false and misleading statements regarding its business operations and financial prospects during the Class Period from February 26, 2025, to February 24, 2026 [1] - The lawsuit claims that due to an algorithm change by Oddity's largest advertising partner, the company's advertisements were diverted to lower quality auctions at abnormally high costs, significantly increasing customer acquisition costs [1] - The defendants are accused of overstating the strength, stability, and sustainability of Oddity's digital operating model and market position, leading to materially false and misleading public statements [1] Legal Proceedings - Investors who purchased Oddity securities during the Class Period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [1] - A lead plaintiff must move the Court by May 11, 2026, to represent other class members in directing the litigation [1] - The Rosen Law Firm has a strong track record in securities class actions, having achieved significant settlements for investors in the past [1]

Core Points - CoreWeave, Inc. is facing a securities fraud lawsuit, with a lead plaintiff deadline set for March 13, 2026, for investors who purchased securities between March 28, 2025, and December 15, 2025 [1] - The lawsuit alleges that CoreWeave made false and misleading statements regarding its ability to meet customer demand and the risks associated with its reliance on a single third-party data center supplier [1] - Investors who suffered losses exceeding $100,000 during the class period may be entitled to compensation without upfront fees through a contingency fee arrangement [1] Legal Context - The Rosen Law Firm is representing investors in this class action, emphasizing the importance of selecting qualified legal counsel with a successful track record in securities class actions [1] - The firm has previously achieved significant settlements, including the largest securities class action settlement against a Chinese company, and has recovered hundreds of millions of dollars for investors [1] - The lawsuit claims that the misleading statements made by CoreWeave were likely to have a material negative impact on the company's revenue, leading to investor damages when the truth was revealed [1]